ARTICLE | Clinical News

Xience V: Additional Phase III data

May 19, 2008 7:00 AM UTC

Additional data from the single-blind, U.S. Phase III SPIRIT III trial in 1,002 patients showed that Xience V reduced the risk of MACE compared with Taxus Liberte at 2 years follow-up. The MACE rate ...